Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Glioblastoma × amivantamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Neoplasms 1 Locally Recurrent Skin Squamous Cell Carcinoma 1 Glioblastoma 1

Interventions

Temozolomide 40 Radiotherapy 18 Magnetic Resonance Spectroscopy 12 pembrolizumab 11 Specimen Handling 10 Lomustine 10 Bevacizumab 10 Radiation 7 Cyclophosphamide 5 fludarabine 4 Nivolumab 4 Aminolevulinic Acid 4 Transurethral Resection of Bladder 3 Surgical Procedures, Operative 3 Ipilimumab 3 regorafenib 2 olaparib 2 fluciclovine F-18 2 atezolizumab 2 antisecretory factor 2 abemaciclib 2 Standard of Care 2 Restraint, Physical 2 Re-Irradiation 2 Radiotherapy, Intensity-Modulated 2 Palliative Care 2 Oncolytic Virotherapy 2 ONC206 2 Metformin 2 Leukapheresis 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06632236 2025-04-25

5G-EMERALD

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡